טוען...

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers

BACKGROUND. PD-L1 expression and tumor mutational burden (TMB) have emerged as important biomarkers of response to immune checkpoint inhibitor (ICI) therapy. These biomarkers have each succeeded and failed in predicting responders for different cancer types. We sought to describe the PD-L1 expressio...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:JCI Insight
Main Authors: Yarchoan, Mark, Albacker, Lee A., Hopkins, Alexander C., Montesion, Meagan, Murugesan, Karthikeyan, Vithayathil, Teena T., Zaidi, Neeha, Azad, Nilofer S., Laheru, Daniel A., Frampton, Garrett M., Jaffee, Elizabeth M.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society for Clinical Investigation 2019
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6482991/
https://ncbi.nlm.nih.gov/pubmed/30895946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.126908
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!